For several commonly used asthma medications, the current consensus is that: 1. Short-acting β2 agonists (SABA) are not suitable for long-term, single application because they can cause down regulation of β2 receptors on the cell membrane, resulting in clinical “rapid desensitization”. Long-acting β2 agonists (LABA) There is no evidence that LABA causes clinical “drug resistance” and “rapid desensitization” as SABA does. There is no evidence that LABA causes clinical “resistance” and “rapid desensitization” like SABA. However, some data suggest that long-term monotherapy with salmeterol increases mortality in some populations. Therefore, the safety of long-term treatment with LABA is still an issue that requires long-term clinical follow-up and research.3. Inhaled glucocorticoids (ICS) In principle, ICS requires long-term use, and a small number of asthmatic patients may require lifelong ICS treatment